linjc16/ctgov huggingface dataset:
Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo

Study Overview
=================
Brief Summary
-----------------
Investigate and compare the efficacy of H FSH plus HMG Vs HMG alone on oocyte and embryo quality in IcsI patients

Detailed Description
-----------------
70 patients divided in to 2groups Group A controlled ovarian stimulation with H FSH and HHMg Group B controlled ovarian stimulation with HMG alone Results will be discussed later

Official Title
-----------------
Effect of Controlled Ovarian Stimulation With H FSH and HHMg Vs HMG Alone on Oocyte and Embryo Quality in IcsI Patients

Conditions
-----------------
Ovarian Stimulation

Intervention / Treatment
-----------------
* Drug: HHMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infertil women aged from 20_35yr Normal utreus Normal ovaries unexplained infertility no endometriosis Exclusion Criteria: 1 - poor responders to gonadotropin 2-Prior history of more than 3unsucceful ICSI 3-Any malformation of sexual organs

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HMG group<br>Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG | Drug: HHMG<br>* Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG<br>* Other names: Using HHMG for induction;|
| Experimental: H FSH plus HHMG<br>Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation | Drug: HHMG<br>* Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG<br>* Other names: Using HHMG for induction;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between the efficacy of controlled ovarian stimulation with H FSH plus HMG Vs HmG alone on oocyte and embryo quality in IcsI patients | Comparison between the efficacy of controlled ovarian stimulation with H FSH plus HMG Vs HmG alone on oocyte and embryo quality in IcsI patients | 9 months |
Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia

Study Overview
=================
Brief Summary
-----------------
X-linked agammaglobulinemia (XLA) is a humoral primary immunodeficiency in which affected patients have very low levels of peripheral B cells and a profound deficiency of all immunoglobulin isotypes. Mutations in the gene encoding for Bruton's tyrosine kinase (Btk) are responsible for most of the gammaglobulinemia. We tend to investigate the gene mutation and clinical features of Chinese X-linked agammaglobulinemia (XLA) patients, and also examined the relationship between specific Btk gene mutations and severity of clinical presentation.

Conditions
-----------------
Agammaglobulinemia, BTK

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of XLA A.male patients with less than 2% CD19-positive B cells; B.recurrent bacterial infection; C.decreased or absent immunoglobulins in serum Exclusion Criteria for all groups: Presence of other primary immunodeficiency syndromes that do not meet the clinical and laboratory criteria for XLA

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gene mutation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| times of pneumonia |  | 2 years |
Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay

Study Overview
=================
Brief Summary
-----------------
The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.

Detailed Description
-----------------
Collect serum with antibody levels capable of killing pneumococcal bacteria from healthy prevaccinated adults to develop OPA assays for the 13 serotypes in 13-valent pneumococcal conjugate vaccine.

Official Title
-----------------
Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Pneumococcal Opsonophagocytic Assay Development.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Procedure: Large volume blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults 18-70 years of age Must have received 23vPS pneumococcal vaccine Exclusion Criteria: Bleeding diathesis Pregnancy Chronic disease which could be worsened by donating blood Receipt of blood, blood products or immune globulin within six months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: All subjects<br>All subjects | Procedure: Large volume blood draw<br>* Large volume blood draw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify potential serum donors and obtain unit volumes of blood from these donors for use in pneumococcal opsonophagocytic assay development. |  | 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccines, Pneumococcal Conjugate Vaccine, Adult
Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment

Study Overview
=================
Brief Summary
-----------------
Evaluate the safety, tolerability and effectiveness of mucopolysaccharide polysulfate in the treatment of superficial varicose veins

Official Title
-----------------
PHASE III OF SAFETY AND EFFICACY STUDY OF TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G IN THE SUPERFICIAL VARICOSE VEINS TREATMENT

Conditions
-----------------
VARICOSE VEINS

Intervention / Treatment
-----------------
* Drug: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be able to understand the study procedures, agree to participate, and give written consent. Patients must be able to follow the study medication regimen. Patients with inflammatory process in superficial veins for more than 72 hours. Presence of symmetric lesions to compare one side to the other. Exclusion Criteria: Pregnancy or risk of pregnancy. Lactation. Use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study Any alteration at other deep veins. History of atopy or allergic diseases. History of allergy to any component of the formulations. Other conditions considered by the investigator as reasonable for non-eligibility.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: GROUP 2<br> | Drug: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G<br>* APLIED 4 TIMES/DAY AT LESION<br>|
| Experimental: GROUP 1<br> | Drug: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G<br>* APLIED 4 TIMES/DAY AT LESION<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy - Symptoms reduction | The primary outcome measure will be evaluated for: Lesion area reduction, reduction of symptoms time and edema. | Evaluation time: 3 - 7 - 10 and 15 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy - patient evaluation | The secondary outcome measure will be measured by subjective opinion (daily register. | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SUPERFICIAL VARICOSE VEINS
Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)

Official Title
-----------------
Long Term Adherence and Efficacy of Etanercept in SpA Iraqi Patients: 7 Year Data From Local Registry

Conditions
-----------------
Spondyloarthrosis

Intervention / Treatment
-----------------
* Drug: Etanercept


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed SpA patients 18 years of age and older. Did not receive previous other biological treatments. Patients have at least 1 year on Enbrel. Exclusion Criteria: Had previously used another biological treatments. Use of etanercept for less than 1 year duration.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with spondyloarthropathies<br>Patients with spondyloarthrosis that received Etanercept as treatment for disease | Drug: Etanercept<br>* Patients with spondyloarthrosis as provided in real world practice<br>* Other names: Enbrel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With 7 Years Adherence to Etanercept | In this outcome measure, percentage of participants who continued etanercept treatment and adhered to the treatment for 7 years were reported. | 7 years [from the data retrieved and observed in 1 month of this study] |
Sacral Nerve Modulation in IPAA Patients With Poor Function

Study Overview
=================
Brief Summary
-----------------
IPAA patients with poor functional outcome where no obvious reason can be detected are identified from our patient registry. These patients are offered a sacral nerve modulation test period of three weeks. They will then be scored on function and physiological testing will be done by a Barostat. After a another 14 days without stimulation the tests will be repeated. Those who respond positively will be offered permanent implantation of the Device..

Official Title
-----------------
Sacral Nerve Modulation in IPAA Patients With Poor Function

Conditions
-----------------
Stoma Malfunction

Intervention / Treatment
-----------------
* Device: Sacral nerve modulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UC With IPAA Bad functional outcome Exclusion Criteria: Established treatable cause of malfunction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: malfunctioning IPAA<br>Patients with malfunctioning IPAA | Device: Sacral nerve modulation<br>* Implant of nerve stimulator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Øresland Score | functional score | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bowel physiology | Barostat | At inclusion and at 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IPAA (Ileal Pouch-Anal Anastomosis), SNM (Sacral Nerve Modultion)
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy

Study Overview
=================
Brief Summary
-----------------
In view of sparse data of precise definition, risk factors, natural history and management of bladder perforation following Transurethral resection of bladder tumour (TURBT). We aim to correlate the relation between the site, depth and extent of resection with bladder perforation. Also, correlation between vertical depth, horizontal extent of resection and recurrence and progression of tumor

Official Title
-----------------
Bladder Perforation Post-TURBT: Definition, Incidence and Natural History. A Prospective Cohort Study

Conditions
-----------------
Injuries, Recurrence Tumor, Bladder Cancer, Bladder Urothelial Carcinoma, Trauma, Perforation of Bladder, Resection Margin, Seeding, Neoplasm

Intervention / Treatment
-----------------
* Diagnostic Test: Computed tomographic cystography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: papillary bladder tumor (denovo or recurrent) resectable nodular bladder tumor Exclusion Criteria: Refuse to complete study requirements muscle invasive bladder tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: TURBT<br>Transurethral resection of bladder tumour | Diagnostic Test: Computed tomographic cystography<br>* CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.<br>* Other names: CT cystography;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of bladder perforation post-Transurethral resection of bladder tumour | calculate the numbers of bladder perforation diagnosed by CT cystogram divided by the total number of patients | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between the cystoscopical and radiological bladder perforation | compare the numbers of bladder perforation diagnosed by CT cystogram by the number of bladder perforation described by surgeon | 24 months | 
| assess the recurrence free rate in bladder perforation groups at 2 year follow up | calculate the number of recurrence pf bladder tumor in bladder perforation at 2 year follow up | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perforation of Bladder, Bladder Cancer, Resection Margin
A Study to Assess CSF1R-related Leukoencephalopathy After Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy.

Official Title
-----------------
Longitudinal Assessment of CSF1R-Related Leukoencephalopathy Following Stem Cell Transplantation

Conditions
-----------------
ALSP, CSF1R-related Leukoencephalopathy, POLD, Hematopoietic Stem Cell Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years of age. Genetic confirmation of a mutation in the CSF1R gene. Diagnosis of CSF1R-related leukoencephalopathy. Anticipated to undergo haematopoietic stem cell transplantation (HSCT). Exclusion Criteria: Concurrent diagnoses that may confound neuropsychological testing; e.g., major hearing/visual impairment. Concurrent diagnoses that may confound ambulatory measurements; e.g., amputee. Inability to undergo magnetic resonance imaging (MRI); e.g., MR-incompatible implant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in cognitive and motor function | Number of participants to demonstrate stability/improvements in cognitive and motor function by detailed clinical assessment and radiographic markers of disease. | Through study completion, approximately 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HDLS, Leukoencephalopathy
Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if rapid on-site evaluation of EBUS-TBNA samples can increase the percentage of patients with advanced non-squamous non-small cell lung cancer in whom both pathologic subtyping and mutational analysis are obtained.

Official Title
-----------------
Mutational Analysis of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Specimens in Patients With Advanced Non-small Cell Lung Cancer: a Randomized Trial of Rapid On-site Evaluation

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Other: Rapid on-site evaluation
* Device: EBUS-TBNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Suspected hilar or mediastinal lymph node metastasis from lung cancer Exclusion Criteria: Pregnancy Uncontrolled coagulopathy Refusal to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EBUS-TBNA + Rapid on-site evaluation<br>Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA | Other: Rapid on-site evaluation<br>* Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.<br>Device: EBUS-TBNA<br>* EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy<br>|
| Active Comparator: EBUS-TBNA<br>Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation | Device: EBUS-TBNA<br>* EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mutational analysis of epidermal growth factor receptor (EGFR), K-ras, and ALK (anaplastic lymphoma kinase) genes | Percentage of patients for whom the mutational analysis of epidermal growth factor receptor (EGFR), K-ras, and ALK (anaplastic lymphoma kinase) genes on EBUS-TBNA samples is obtained | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic yield of EBUS-TBNA |  | 18 months | 
| Adequacy of EBUS-TBNA samples |  | 18 months |